DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer
- 1 March 2021
- journal article
- research article
- Published by Elsevier in Chemistry and Physics of Lipids
- Vol. 235, 105033
Abstract
No abstract availableKeywords
Funding Information
- DST
- FIST
- Ministry of Science & Technology, New Delhi
This publication has 28 references indexed in Scilit:
- Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiencyBreast Cancer Research, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicityBreast Cancer Research and Treatment, 2011
- Effect of anti-DR5 and chemotherapy on basal-like breast cancerBreast Cancer Research and Treatment, 2011
- Mesoporous Silica Nanoparticles as Drug Delivery Systems for Targeted Inhibition of Notch Signaling in CancerMolecular Therapy, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast CancerClinical Breast Cancer, 2009
- PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicityBreast Cancer Research and Treatment, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Notch Signaling, γ-Secretase Inhibitors, and Cancer TherapyCancer Research, 2007